Document is current

Article History

Received: 27 January 2022

Revised: 1 April 2022

Accepted: 11 April 2022

First Online: 25 April 2022

Competing interests

: EP: received support for the present manuscript from the Princes Maxima Center. NM: received support for the present manuscript from the Princes Maxima Center. EB: received support for the present manuscript from the Princes Maxima Center. YJ: received support for the present manuscript from the Princes Maxima Center. BS: is Pfizer Inc Employee and Pfizer Inc stock holder. YC: is Pfizer Inc Employee and Pfizer Inc stock holder. BV: is in the Advisory Board for DSMB SeluDex Study. SR: is in the advisory boards of Novartis, Celgene/Bristol-Myers, Servier/Cellectis Kite and Amgen from which received travel expenses reimbursement, and is Co-chair of the Leukemia Group of the Spanish Pediatric Hematology and Oncology Society (SEHOP) (not paid), and National Representative of Spain in the I-BFM Study Group of Childhood Leukemia (not paid). CR (Claudia Rössig): received consulting fees from Amgen, Pfizer, BMS, Novartis, Celgene, Roche. CR: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Jazz pharmaceuticals, Servier, Amgen, and support for attending meetings and/or travel from Jazz pharmaceuticals, Servier, Amgen, Gilead. GE: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier. FJBS: received consulting fees from Bayer, Agmen Roche Genentech, EusaPharma, and is speaker at Symposia for Roche Genentech. YB: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier, Sanofi Genzymea and financial support for attending meetings from Jazz pharmaceuticals and Servier. DR: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Cerus. LV: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Agmen and financial support for attending meetings and/or travel from Interlabo. AvS: received consulting fees from Amgen, Novartis and Jazz Pharmaceuticals, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis and Miltenyi. FL: received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Miltenyi, Bellicum, Medac, Neovii, BluebirdBio, and Gilead. CMZ: received financial support for the present manuscript from Pfizer Inc, grants or contracts from any entity from BMS, Abbvie and JAZZ pharmaceuticals, consulting fees from Sanofi, Novartis, Roche, Pfizer Inc and Incyte, financial support for attending meetings and/or travel from JAZZ pharmaceuticals.